ROCKET PHARMACEUTICALS, INC. (RCKT) 8-K Current Report: March 10, 2026
Filed: March 10, 2026
Health Care
Pharmaceutical PreparationsROCKET PHARMACEUTICALS, INC. (RCKT) 8-K current report filed with SEC EDGAR on March 10, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 1.01: Entry into a Material Definitive Agreement
- Item 1.02: Termination of a Material Definitive Agreement
ROCKET PHARMACEUTICALS, INC. 8-K Mar 10, 2026 Event Analysis
Item 1.01 · Entry into a Material Definitive Agreement
- • ATM offering up to $100M in common stock via Cantor Fitzgerald, filed March 10, 2026 under existing S-3 shelf registration
- • Sales agent commission up to 3.0% of gross proceeds — maximum dilution cost ~$3M if fully drawn
- • Company controls timing, volume, and minimum price floor; no obligation to sell any shares
- • Signals potential near-term cash needs for pipeline development or operational runway extension
- • Investors should monitor actual share sales via Form 424B3 prospectus supplements for real-time dilution tracking
Item 1.02 · Termination of a Material Definitive Agreement
- • Rocket Pharma terminated its prior ATM agreement with Cowen and Company (TD Securities affiliate), originally dated Feb 28, 2022
- • Termination triggered by entry into a new Sales Agreement, signaling a change in ATM program counterparty or structure
- • Prior ATM allowed open-ended at-the-market common stock sales — termination removes that existing dilution channel, replaced by new one
Other ROCKET PHARMACEUTICALS, INC. 8-K Filings
Get deeper insights on ROCKET PHARMACEUTICALS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.